GO:0097169 AIM2 inflammasome complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097169 (AIM2 inflammasome complex) is a cytosolic innate immune complex composed of AIM2, ASC (PYCARD), and caspase-1 that senses double-stranded DNA.
• AIM2 is a member of the HN-200 protein family and acts as the sensor of cytosolic double-stranded DNA, triggering inflammasome assembly.
• Assembly of the AIM2 inflammasome leads to caspase-1 activation, pyroptosis, and release of IL-1beta and IL-18.
• AIM2 can form higher-order complexes with pyrin and ZBP1 to drive PANoptosis, a lytic cell death pathway integrating pyroptosis, apoptosis, and necroptosis.
• Dysregulated AIM2 inflammasome activity is implicated in inflammatory diseases, tendinopathy, alcoholic liver disease, and host defence against pathogens.
• CRISPR-based knockout, knock-in, and overexpression models are essential tools for dissecting AIM2 inflammasome complex function in disease.
Description
The AIM2 inflammasome complex (GO:0097169) is a cytosolic multiprotein complex that serves as a critical sensor of double-stranded DNA and a key effector of innate immunity. It is defined by the presence of three core components: AIM2 (absent in melanoma 2), ASC (apoptosis-associated speck-like protein containing a CARD, encoded by PYCARD), and caspase-1. AIM2 belongs to the HN-200 protein family and directly binds cytosolic double-stranded DNA, a danger signal released during infection or cellular stress. This binding triggers inflammasome assembly and downstream inflammatory signalling, making GO:0097169 a central node in host defence and inflammatory pathology. Researchers study the AIM2 inflammasome complex because of its dual role in protective immunity and tissue-damaging inflammation. Its activation leads to caspase-1-dependent maturation of pro-inflammatory cytokines IL-1beta and IL-18 and to pyroptotic cell death, which is essential for clearing intracellular pathogens but can also exacerbate chronic inflammatory conditions. Recent work has shown that AIM2 can cooperate with pyrin and ZBP1 to form a larger PANoptosome, driving PANoptosis, a lytic cell death modality that integrates pyroptosis, apoptosis, and necroptosis. Understanding the molecular composition, assembly, and regulation of GO:0097169 is therefore fundamental for immunology, infectious disease, and inflammation research. This article provides a research-grade overview of the AIM2 inflammasome complex, covering its definition, structure, molecular mechanism, key genes, disease relevance, and the CRISPR-based methods used to study it.
AIM2 inflammasome complex At A Glance
| GO ID | GO:0097169 |
|---|---|
| GO term | AIM2 inflammasome complex |
| Ontology | cellular_component |
| Synonym | None |
| Definition | An inflammasome complex that consists of AIM2, ASC, and caspase-1. AIM2 is a member of the HN-200 protein family that appears to be the sensor of cytosolic double-stranded DNA. |
| Major function | Sensing cytosolic double-stranded DNA and triggering inflammasome assembly, caspase-1 activation, and pyroptosis. |
| Core components | AIM2 (sensor), ASC/PYCARD (adaptor), caspase-1 (effector). |
| Associated processes | Innate immunity, pyroptosis, PANoptosis, cytokine maturation. |
| Disease relevance | Inflammatory diseases, tendinopathy, alcoholic liver disease, host defence. |
What Is GO:0097169?
The AIM2 inflammasome complex (GO:0097169) is a cellular component defined as an inflammasome complex that consists of AIM2, ASC, and caspase-1. AIM2 is a member of the HN-200 protein family and appears to be the sensor of cytosolic double-stranded DNA. In this complex, AIM2 recognizes double-stranded DNA, ASC acts as an adaptor, and caspase-1 is the effector protease that becomes activated upon assembly.
Why Is AIM2 inflammasome complex Important in Cell Biology?
The AIM2 inflammasome complex is important because it is a primary cytosolic sensor of double-stranded DNA, a danger signal that indicates infection or cellular damage. Its activation is essential for host defence against intracellular pathogens, but excessive or chronic activation contributes to inflammatory diseases such as tendinopathy and alcoholic liver disease. Furthermore, AIM2 can integrate with other innate sensors to drive PANoptosis, a cell death pathway with broad implications for infection, autoimmunity, and cancer. Understanding GO:0097169 is therefore critical for developing targeted therapies that modulate inflammation without compromising immunity.
• Serves as the primary cytosolic sensor of double-stranded DNA, a key danger signal in infection and tissue damage.
• Drives caspase-1 activation and maturation of IL-1beta and IL-18, central mediators of inflammation.
• Induces pyroptosis, a lytic cell death that restricts pathogen replication but can cause tissue injury.
• Cooperates with pyrin and ZBP1 to form PANoptosomes and drive PANoptosis.
• Implicated in inflammatory diseases including tendinopathy and alcoholic liver disease.
• Essential for host defence against intracellular bacteria and viruses.
• Target for small-molecule inhibitors and autophagy modulators to treat inflammatory conditions.
• Provides a model system for studying inflammasome assembly and signalling.
• Relevant to cancer immunology through its role in inflammation and cell death.
• Enables CRISPR-based functional genomics of innate immune pathways.
What Happens During AIM2 inflammasome complex?
DNA sensing and AIM2 activation
In simple terms: AIM2 detects DNA that has escaped into the cell cytoplasm and switches on.
AIM2 is a member of the HN-200 protein family and functions as the sensor of cytosolic double-stranded DNA. Upon binding double-stranded DNA, AIM2 undergoes a conformational change that exposes its pyrin domain, enabling recruitment of the adaptor ASC. This DNA-sensing step is the initiating event for AIM2 inflammasome complex assembly.
Inflammasome assembly and ASC speck formation
In simple terms: AIM2 and ASC gather into a large cluster that acts as a signalling platform.
After DNA binding, AIM2 nucleates the assembly of ASC into large helical filaments, forming a speck-like structure. ASC recruitment is mediated by pyrin-pyrin domain interactions, and ASC in turn recruits pro-caspase-1 through CARD-CARD interactions. This assembly converts the AIM2 inflammasome complex into an active signalling platform.
Caspase-1 activation and cytokine maturation
In simple terms: Caspase-1 becomes active and cuts pro-inflammatory cytokines into their mature forms.
Within the assembled AIM2 inflammasome complex, pro-caspase-1 undergoes proximity-induced autoactivation. Active caspase-1 cleaves pro-IL-1beta and pro-IL-18 into their mature, secreted forms, which drive fever, inflammation, and immune cell recruitment. Caspase-1 also cleaves gasdermin D to initiate pyroptosis.
Pyroptosis and PANoptosis
In simple terms: The cell can undergo a lytic death that releases inflammatory contents.
Caspase-1-mediated cleavage of gasdermin D triggers pyroptosis, a lytic form of cell death that releases IL-1beta, IL-18, and other danger signals. AIM2 can also form a complex with pyrin and ZBP1 to drive PANoptosis, a cell death modality integrating pyroptosis, apoptosis, and necroptosis. PANoptosis is emerging as a critical host defence mechanism and a driver of inflammatory pathology.
Resolution and regulation
In simple terms: The complex is kept in check by degradation and autophagy.
AIM2 inflammasome activity is regulated by selective autophagy, which targets AIM2 and ASC for degradation to prevent excessive inflammation. Pharmacological agents such as pristimerin can promote AIM2-PYCARD/ASC degradation via autophagy, alleviating tendinopathy. Bruceine A inhibits AIM2 inflammasome activation by activating FXR, suggesting additional regulatory nodes.
Key Genes Involved in GO:0097169 AIM2 inflammasome complex
The AIM2 inflammasome complex involves a core set of genes and proteins that mediate DNA sensing, adaptor function, and effector protease activity, as well as regulatory and interacting partners.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AIM2 | Cytosolic double-stranded DNA sensor; nucleates inflammasome assembly | Central to GO:0097169; knockout and knock-in models reveal DNA sensing mechanisms |
| PYCARD (ASC) | Adaptor protein linking AIM2 to caspase-1 via pyrin and CARD domains | Essential for speck formation; targeted for degradation by autophagy modulators |
| CASP1 | Effector protease that matures IL-1beta and IL-18 and cleaves gasdermin D | Readout of inflammasome activation; knockout blocks pyroptosis |
| ZBP1 | DNA/RNA sensor that cooperates with AIM2 to drive PANoptosis | Key for understanding AIM2-PANoptosome crosstalk |
| MEFV (Pyrin) | Inflammasome sensor that interacts with AIM2 in PANoptosis | Links AIM2 to pyrin-driven inflammation |
| NLRP3 | Inflammasome sensor that can co-activate with AIM2 in PANoptosis | Comparative studies of inflammasome crosstalk |
| NLRC4 | Inflammasome sensor activated by bacterial flagellin, co-drives PANoptosis | Used to dissect integrated inflammasome signalling |
| GSDMD | Gasdermin D, pore-forming executioner of pyroptosis downstream of caspase-1 | Marker of pyroptosis; knockout prevents lysis |
| IL1B | Pro-inflammatory cytokine matured by caspase-1 | Readout of AIM2 inflammasome activity |
| IL18 | Pro-inflammatory cytokine matured by caspase-1 | Readout of AIM2 inflammasome activity |
| FXR (NR1H4) | Nuclear receptor that inhibits AIM2 inflammasome activation | Target for alcoholic liver disease intervention |
| RIPK1 | Kinase involved in PANoptosis downstream of innate sensors | Modulates cell death outcomes |
| RIPK3 | Kinase involved in necroptosis and PANoptosis | Modulates cell death outcomes |
| MLKL | Executioner of necroptosis in PANoptosis | Marker of PANoptosis |
| NLRP10 | Inflammasome sensor activated by mitochondrial damage | Comparative inflammasome biology |
| ATG5 | Autophagy machinery component that regulates AIM2 stability | Links autophagy to inflammasome control |
| ATG7 | Autophagy machinery component that regulates AIM2 stability | Links autophagy to inflammasome control |
| SQSTM1 (p62) | Selective autophagy receptor for AIM2-PYCARD degradation | Target for modulating inflammasome turnover |
How Is AIM2 inflammasome complex Regulated?
The AIM2 inflammasome complex is regulated at multiple levels. Selective autophagy targets AIM2 and ASC for degradation, thereby limiting inflammasome activation; pharmacological induction of autophagy with pristimerin suppresses AIM2 inflammasome activity and alleviates tendinopathy. The nuclear receptor FXR inhibits AIM2 inflammasome activation, and its activation by Bruceine A alleviates alcoholic liver disease. Additionally, crosstalk with other inflammasome sensors such as NLRP3, NLRC4, and pyrin can modulate AIM2-driven responses and PANoptosis. Small-molecule inhibitors of inflammasomes, such as MCC950 for NLRP3, provide proof of concept for pharmacological control of these pathways.
AIM2 inflammasome complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AIM2 | Tendinopathy, alcoholic liver disease, host defence | AIM2 knockout mice or cell lines; overexpression models |
| PYCARD (ASC) | Inflammatory diseases, pyroptosis | ASC knockout and tagged knock-in for imaging |
| CASP1 | Inflammatory diseases, pyroptosis | Caspase-1 knockout; point mutation of catalytic cysteine |
| ZBP1 | PANoptosis, host defence | ZBP1 knockout; AIM2-ZBP1 double knockout |
| FXR (NR1H4) | Alcoholic liver disease | FXR knockout and agonist treatment models |
Inflammatory and musculoskeletal diseases
AIM2 inflammasome activation contributes to tendinopathy, where excessive inflammation drives tissue damage. Pristimerin suppresses the AIM2 inflammasome by promoting AIM2-PYCARD/ASC degradation via selective autophagy, reducing inflammation in tendinopathy models. This highlights the AIM2 inflammasome complex as a therapeutic target in inflammatory musculoskeletal conditions.
Liver disease
In alcoholic liver disease, AIM2 inflammasome activation exacerbates hepatic inflammation. Bruceine A alleviates alcoholic liver disease by inhibiting AIM2 inflammasome activation via activation of FXR, suggesting that FXR agonists may be beneficial. These findings link GO:0097169 to metabolic and inflammatory liver pathology.
Host defence and PANoptosis
The AIM2 inflammasome complex is essential for host defence against intracellular pathogens through DNA sensing and pyroptosis. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis, a cell death pathway critical for restricting pathogen replication. Dysregulation of PANoptosis can contribute to inflammatory diseases and may influence cancer immunity.
Emerging roles in cancer and other diseases
Chronic inflammation driven by inflammasomes, including AIM2, is implicated in tumorigenesis and autoimmune conditions. Understanding the molecular mechanisms of AIM2 inflammasome activation and its integration with PANoptosis may reveal new therapeutic opportunities. Comparative studies of emerging inflammasome complexes, such as NLRP10, provide broader context for AIM2 biology.
From AIM2 inflammasome complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AIM2 mediate DNA sensing in a specific cell type? | AIM2 knockout cell line or mouse model |
| What is the role of ASC in AIM2 inflammasome assembly? | PYCARD/ASC knockout with reconstitution of tagged ASC |
| Is caspase-1 catalytic activity required for pyroptosis? | CASP1 point mutation (catalytic dead) knock-in |
| How does AIM2 interact with ZBP1 and pyrin during PANoptosis? | AIM2-ZBP1 or AIM2-MEFV double knockout; tagged knock-in for imaging |
| Can overexpression of AIM2 drive spontaneous inflammation? | AIM2 overexpression cell lines and transgenic models |
| What genes regulate AIM2 inflammasome stability? | CRISPR library screening with readouts of ASC speck formation |
How to Study the AIM2 inflammasome complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on inflammasome activation | Identify novel regulators of AIM2 inflammasome |
| ASC speck imaging | Inflammasome assembly and aggregation | Visualize AIM2 inflammasome complex formation |
| IL-1beta ELISA | Caspase-1-dependent cytokine maturation | Quantify AIM2 inflammasome activity |
| LDH release assay | Pyroptotic cell death | Measure cytotoxicity downstream of AIM2 |
| Co-immunoprecipitation | Protein-protein interactions | Detect AIM2-ASC and AIM2-ZBP1 complexes |
| Western blot | Cleaved caspase-1 and gasdermin D | Confirm inflammasome activation |
| Proteomics | Protein composition and modifications | Define AIM2 interactome |
| Autophagy flux assays | AIM2 and ASC degradation | Study regulation by selective autophagy |
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify genes that regulate AIM2 inflammasome assembly and activity. Readouts include ASC speck formation, caspase-1 activation, and IL-1beta secretion. These screens are powerful for discovering novel regulators of GO:0097169.
Imaging and biochemical assays
Fluorescence microscopy of ASC specks and AIM2 localization is used to monitor inflammasome assembly. Co-immunoprecipitation and proximity ligation assays can detect AIM2-ASC and AIM2-ZBP1 interactions. These methods provide spatial and temporal resolution of complex formation.
Cytokine and cell death assays
ELISA for IL-1beta and IL-18, and LDH release assays for pyroptosis, are standard readouts of AIM2 inflammasome activation. Western blotting for cleaved caspase-1 and gasdermin D confirms pathway activation. These assays are used to test genetic and pharmacological perturbations.
Proteomics and interactomics
Affinity purification coupled to mass spectrometry can identify AIM2-associated proteins and post-translational modifications. Proteomic profiling of inflammasome complexes helps define the composition of GO:0097169 under different conditions. These approaches complement genetic screens.
How CRISPR Can Be Used to Study GO:0097169 AIM2 inflammasome complex
Knockout
CRISPR knockout of AIM2, PYCARD, or CASP1 is used to abolish AIM2 inflammasome complex function and test its role in DNA sensing, cytokine release, and pyroptosis. Knockout models are essential for validating specificity of pharmacological inhibitors. They also enable epistasis experiments with ZBP1 and pyrin.
Point Mutation
Point mutations can be introduced into CASP1 to generate catalytically dead caspase-1, or into AIM2 to disrupt DNA binding, allowing structure-function analysis of GO:0097169. Such models help distinguish enzymatic activity from scaffolding functions. They are also useful for studying post-translational modification sites.
Knock-in
Knock-in of epitope tags or fluorescent proteins into AIM2, PYCARD, or CASP1 enables real-time imaging and biochemical isolation of the AIM2 inflammasome complex. Tagged knock-in models preserve endogenous regulation and are superior to overexpression for physiological studies. They facilitate proximity proteomics and live-cell tracking.
Overexpression
Overexpression of AIM2 or ASC can drive spontaneous inflammasome assembly and is useful for gain-of-function studies. However, overexpression may bypass regulatory checkpoints, so results should be validated with endogenous models. Overexpression systems are valuable for screening inhibitors.
How EDITGENE Supports AIM2 inflammasome complex Research
Researchers studying AIM2 inflammasome complex-related genes often need to determine whether a candidate gene is causally involved in DNA sensing, inflammasome assembly, or downstream cell death. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for AIM2 inflammasome complex research.
Frequently Asked Questions About AIM2 inflammasome complex
What is the AIM2 inflammasome complex?
The AIM2 inflammasome complex (GO:0097169) is a cytosolic multiprotein complex composed of AIM2, ASC, and caspase-1 that senses double-stranded DNA and triggers inflammatory responses.
What genes are involved in the AIM2 inflammasome complex?
Core genes include AIM2, PYCARD (ASC), and CASP1, with additional partners such as ZBP1, MEFV, GSDMD, IL1B, and IL18.
How is the AIM2 inflammasome activated?
AIM2 binds cytosolic double-stranded DNA, recruits ASC, and activates caspase-1, leading to cytokine maturation and pyroptosis.
What diseases are associated with the AIM2 inflammasome?
AIM2 inflammasome dysregulation is linked to tendinopathy, alcoholic liver disease, and impaired host defence, among other inflammatory conditions.
What is PANoptosis and how does AIM2 contribute?
PANoptosis is a lytic cell death pathway integrating pyroptosis, apoptosis, and necroptosis; AIM2 forms a complex with pyrin and ZBP1 to drive it.
How can I study the AIM2 inflammasome complex in the lab?
Common methods include CRISPR knockout, ASC speck imaging, cytokine ELISA, LDH release, and co-immunoprecipitation.
What is the role of ASC in the AIM2 inflammasome?
ASC (PYCARD) is an adaptor that bridges AIM2 and caspase-1 through pyrin and CARD domain interactions, forming a speck-like platform.
Can the AIM2 inflammasome be inhibited therapeutically?
Yes, compounds such as pristimerin and Bruceine A inhibit AIM2 inflammasome activation via autophagy or FXR pathways.
What is the difference between AIM2 and NLRP3 inflammasomes?
AIM2 senses double-stranded DNA, whereas NLRP3 responds to diverse danger signals; they can co-activate in PANoptosis.
What CRISPR models are available for AIM2 inflammasome research?
Knockout, point mutation, knock-in, and overexpression models for AIM2, PYCARD, CASP1, and related genes are available from EDITGENE.
Conclusion
The AIM2 inflammasome complex (GO:0097169) is a central component of cytosolic DNA sensing and innate immunity, with critical roles in host defence, inflammatory diseases, and cell death pathways such as pyroptosis and PANoptosis. Its core components AIM2, ASC, and caspase-1 are tightly regulated by autophagy and other mechanisms, offering multiple therapeutic entry points. Continued research using CRISPR-based models will further elucidate its molecular mechanisms and disease relevance.
References
- 1. Lee S et al.. 2021. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence.. Nature 597(7876):415-419 PMID: 34471287
- 2. Jiang H et al.. 2024. Pristimerin suppresses AIM2 inflammasome by modulating AIM2-PYCARD/ASC stability via selective autophagy to alleviate tendinopathy.. Autophagy 20(1):76-93 PMID: 37647255
- 3. Oh S et al.. 2023. Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis.. Cell Mol Immunol 20(12):1513-1526 PMID: 38008850
- 4. Pandeya A et al.. 2024. Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes.. Trends Mol Med 30(1):74-88 PMID: 37977994
- 5. Coll RC et al.. 2015. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.. Nat Med 21(3):248-55 PMID: 25686105
- 6. Li L et al.. 2024. Bruceine A alleviates alcoholic liver disease by inhibiting AIM2 inflammasome activation via activating FXR.. Phytomedicine 130:155693 PMID: 38763006
- 7. Próchnicki T et al.. 2023. Mitochondrial damage activates the NLRP10 inflammasome.. Nat Immunol 24(4):595-603 PMID: 36941400
- 8. Pandey A et al.. 2025. Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis.. Immunol Rev 329(1):e13406 PMID: 39351983
